Golden State Equity Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Golden State Equity Partners’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35	Closed	-$2.04K	–	1768
2026 Q1	$2.04K	Buy	+35	New	+$1.61K	﹤0.01%	1676

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Golden State Equity Partners's XENE Position: Q2 2026 in Review

Golden State Equity Partners sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 35 shares — an estimated $2.04K sold.

Golden State Equity Partners first reported a position in XENE in Q1 2026 and held it in 1 quarter. The position peaked at $2.04K in Q1 2026. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Golden State Equity Partners reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Golden State Equity Partners sold 35 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.04K.
Golden State Equity Partners first reported a position in Xenon Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Golden State Equity Partners's Xenon Pharmaceuticals position peaked at $2.04K in Q1 2026.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.